A CD4+, HLA-DR7-restricted T-helper lymphocyte clone recognizes an antigen shared by human malignant melanoma and glioma

International Journal of Cancer

Volumn 104, Issue 3, 2003, Pages 362-368

  Somasundaram, Rajasekharan ^a   Swoboda, Rolf ^a   Caputo, Laura ^a   Lee, Allana ^a   Jackson, Naidine ^a   Marincola, Francesco M ^b   Guerry, DuPont ^c,d   Herlyn, Dorothee ^a,d  

^a WISTAR INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CD4+; Glioma; Melanoma; Shared antigen; T helper cell

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; HLA DR7 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC RESTRICTION; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL LYSATE; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EPSTEIN BARR VIRUS; GLIOMA; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IRRADIATION; LYMPHOCYTE CLONE; LYMPHOCYTE TRANSFORMATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; PRIORITY JOURNAL; TUMOR IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; CLONE CELLS; COCULTURE TECHNIQUES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GLIOMA; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-DR7 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037431438     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10964     Document Type: Article

References (51)

1. + T helper cell responses in tumor immunity. Immunol Lett 2000;74:75-9.
2. + T cell reactivity to a model tumor antigen. J Immunol 2000;164:562-5.
3. Keene J, Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 1982;155:768-82.
4. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.
5. +, 2-T cells: tumor eradication does not require participation of cytotoxic T cells. J Exp Med 1985;161:1122-34.
6. + cells: cytotoxic T cells can mediate eradication of disseminated leukemia. J Immunol 1986;136:1917-22.
7. Dranoff G, Jaffe E, Lazenby P, Golumbek H, Levitsky K, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
8. + T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
9. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
10. Monach PA, Meredith SC, Siegel CT, Schreiber, H. A unique tumor antigen produced by a single amino acid substitution. Immunity 1995;2:45-59.
11. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995;181:617-29.
12. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994;179:1215-24.
13. Wan Y, Bramson J, Pilon A, Zhu Q, Gauldie J. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Cancer Res 2000;60:3247-53.
14. Hunt DF, Michel H, Dickinson TA, Shabanowitz J, Cox AL, Sakaguchi K, Apella E, Greg HM, Sette A. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-A. Science 1992;256:1817-20.
15. Rudensky AY, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA Jr. Sequence analysis of peptides bound to MHC class-II molecules. Nature 1991;353:622-7.
16. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells. Immunity 2000;12:677-86.
17. + T cells in the immune response to melanoma. Cancer Immunol Immunother 1999;48:363-70.
18. Clemente GC, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303-10.
19. + T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 2000;164:3902-12.
20. Chiari R, Hames G, Stroobant V, Texier C, Maillere B, Boon T, Coulie PG. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res 2000;60:4855-63.
21. + melanoma-infiltrating lymphocytes. Eur J Immunol 1995;25:2732-6.
22. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 189:871-6.
23. Radrizzani M, Benedetti B, Castelli C, Longo A, Ferra GB, Herlyn M, Parmiani G, Fossati G. Human allogeneic melanoma-reactive T-helper lymphocyte clones: functional analysis of lymphocyte-melanoma interactions. Int J Cancer 1991;49:823-30.
24. + T lymphocytes against human melanoma: evidence for a shared melanoma antigen presented by HLA DR15. J Immunol 1995;154:772-9.
25. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus transformed B cells. Int J Cancer 1994;58:69-70.
26. + T cells specially recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994;91:9461-5.
27. + T cells in antitumor immunity. Trends Immunol 2001;22:269-76.
28. + T cells: its role in extracellular matrix formation and tumor metastasis. J Exp Med 2002;195:397-406.
29. + T cells by a single peptide with dual MHC class I and class 11 specificities: a new strategy for vaccine design. Cancer Res 2002;62:3630-5.
30. Halder T, Pawelec G, Kirkin AF, Zeuthen J, Meyer HE, Kun L, Kalbacher H. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res 1997;57:3238-44.
31. Li K, Adibzadeh M, Halder T, Kalbacher H, Heinzel S, Müller C, Zeuthen J, Pawelec G. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother 1998;47:32-8.
32. Clark WH, Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-904.
33. Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, Rendle S, Elder DE, Herlyn M. Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res 1997;7:S35-42.
34. Herlyn D, Iliopoulos D, Jensen P, Parmiter A, Baird J, Hotta H, Adachi K, Ross AH, Jambrosic J, Koprowski H, Herlyn M. In vitro properties of human melanoma cells metastatic in nude mice. Cancer Res 1990;50:2296-302.
35. Jacob L, Somasundaram R, Smith W, Monos D, Basak S, Marincola F, Pereira S, Herlyn D. Cytotoxic T-cell clone against rectal carcinoma induced by stimulation of a patient's peripheral blood mononuclear cells with autologous cultured tumor cells. Int J Cancer 1997;71:325-32.
36. +, HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma. Int J Cancer 2000;85:253-9.
37. Somasundaram R, Zaloudik J, Jacob L, Benden A, Sperlagh M, Hart E, Marks G, Kane M, Mastrangelo M, Herlyn D. Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. J Immunol 1995;155:3253-61.
38. Young JAT, Wilkinson D, Bodmer WF, Trowsdale J. Sequence and evolution of HLA-DR7 and DRw53-associated beta-chain genes. Proc Natl Acad Sci USA 1987;84:4929-33.
39. Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G. T-cell recognition of melanoma-associated antigens. J Cell Physiol 2000;182:323-31.
40. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996;56:2479-83.
41. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996;56:4749-57.
42. Yang JC, Rosenberg SA. Vaccination trials and response monitoring using the defined melanoma-associated antigen MART-1 and gp100. Melanoma Res 1997;7:S24-5.
43. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
44. Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001;291:2413-7.
45. Murali-Krishna K, Lau LL, Sambhara S, Lemonnier F, Altman J, Ahmed R. Persistence of memory CD8 T cells in MHC class I-deficient mice. Science 1999;286:1377-81.
46. Guilloux Y, Xue-feng B, Liu X, Zheng P, Liu Y. Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells. Cancer Res 2001;61:1107-12.
47. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5.
48. Lentner C, ed. Geige Scientific Tables, 8th Ed., Volume 3, Basel, Ciba-Geigy Ltd., 1984, p. 245.
49. + T cells from peripheral blood of a melanoma patient recognize peptides derived from non-mutated tyrosinase. Cancer Res 1998;58:296-301.
50. + T cells. Cancer Res 2002;62:213-8.
51. + T cells. Proc Natl Acad Sci USA 2000;97:400-5.